# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Moderna's Phase 1/2 study shows mRNA-4359 plus pembrolizumab yields 24% response rate and 60% disease control in resistant ...
mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial
Morgan Stanley analyst Matthew Harrison maintains Moderna (NASDAQ:MRNA) with a Equal-Weight and raises the price target from...
Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tari...
Moderna stock is trading higher Wednesday afternoon, lifted by positive sentiment across the pharmaceutical sector.
Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secret...
Moderna, Inc.‘s (NASDAQ: MRNA) UK chief Darius Hughes defended Britain's drug pricing policies after the country was brande...
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply...